It is exciting that in 2022, the research team found a direct action target IGF2BP1 in liver cancer cells, which will provide a feasible reference value for the development and application of cucurbitacin B. However, in order to advance cucurbitacin B and its derivatives into a viable treatment, there are still several questions and new directions for future development to be considered [15]. This evidence concerns the gene IGF2BP1 and liver cancer.